Clarity AD enrolled 1,795 early Alzheimer’s patients, and secondary measures include changes in PET and measures on the Adas-Cog14, Adcoms and ADCS-ADL scales. This statement came in response to a question about what the company would do if Clarity AD failed on CDR-SB yet showed numerical improvement in one or more secondaries. But Priya Singhal, interim R&D head, said the group was considering a range of scenarios for the readout, due in the third quarter, adding: “The totality of the data will be very important.” With Aduhelm confirmed as a disaster, the effectively rudderless Biogen today primed investors for its next big Alzheimer’s readout, the Clarity AD trial of lecanemab, and many might be rolling their eyes at the prospect of yet another failed amyloid-beta MAb study being data dredged.Ĭlarity AD has CDR-SB as its primary endpoint, and Biogen stressed that it was gunning for a positive win here for lecanemab against placebo.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |